Investment Thesis
InMed is a pre-commercial biotech company burning $5.7M annually while generating only $1.9M in revenue, with approximately 11 months of cash runway remaining at current burn rates. Without immediate revenue acceleration, major financing, or dramatic cost reduction, the company faces existential liquidity risk. The 30.3% gross margin indicates a viable product model, but operating expenses dwarf revenue by 6.5x, creating an unsustainable financial structure.
Strengths
- Zero long-term debt - no leverage risk or debt covenants
- Strong current ratio (3.11x) and quick ratio (2.69x) - adequate short-term liquidity
- Positive revenue growth of 7.5% YoY and improving EPS losses by 58.5% - shows modest operational trajectory improvement
Risks
- Critical cash runway - $5.2M cash divided by $5.7M annual burn equals ~11 months until depletion
- Massive operating losses - $6.5M operating loss on $1.9M revenue indicates unsustainable business model at scale
- Negative free cash flow of $5.7M annually with no path to profitability visible in current financials
- Negative operating leverage - company expenses are 3.4x revenue with minimal cost flexibility
- No insider buying activity in 90 days - potential signal of low confidence from management
Key Metrics to Watch
- Quarterly cash balance and burn rate trend - survival metric
- Revenue growth rate acceleration - must exceed burn rate trajectory to achieve viability
- Operating expense reduction - critical for extending runway or achieving profitability
- Product development milestones and FDA progression - determines future revenue potential
Financial Metrics
Revenue
1.9M
Net Income
-6.7M
EPS (Diluted)
$-1.69
Free Cash Flow
-5.7M
Total Assets
9.1M
Cash
5.2M
Profitability Ratios
Gross Margin
30.3%
Operating Margin
-336.5%
Net Margin
-346.4%
ROE
-97.5%
ROA
-73.6%
FCF Margin
-293.2%
Balance Sheet & Liquidity
Current Ratio
3.11x
Quick Ratio
2.69x
Debt/Equity
0.00x
Debt/Assets
24.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:41:26.543303 |
Data as of: 2026-03-31 |
Powered by Claude AI